Plac1: Biology and Potential Application in Cancer Immunotherapy Publisher Pubmed



Mahmoudian J^{1, 2} ; Ghods R^{3, 4} ; Nazari M² ; Jedditehrani M² ; Ghahremani MH^{1, 5} ; Ghaffaritabriziwizsy N⁶ ; Ostad SN^{1, 5} ; Zarnani AH^{7, 8, 9}
Source: Cancer Immunology# Immunotherapy Published:2019

Abstract

The emergence of immunotherapy has revolutionized medical oncology with unprecedented advances in cancer treatment over the past two decades. However, a major obstacle in cancer immunotherapy is identifying appropriate tumor-specific antigens to make targeted therapy achievable with fewer normal cells being impaired. The similarity between placentation and tumor development and growth has inspired many investigators to discover antigens for effective immunotherapy of cancers. Placenta-specific 1 (PLAC1) is one of the recently discovered placental antigens with limited normal tissue expression and fundamental roles in placental function and development. There is a growing body of evidence showing that PLAC1 is frequently activated in a wide variety of cancer types and promotes cancer progression. Based on the restricted expression of PLAC1 in testis, placenta and a wide variety of cancers, we have designated this molecule with new terminology, cancer–testis–placenta (CTP) antigen, a feature that PLAC1 shares with many other cancer testis antigens. Recent reports from our lab provide compelling evidence on the preferential expression of PLAC1 in prostate cancer and its potential utility in prostate cancer immunotherapy. PLAC1 may be regarded as a potential CTP antigen for targeted cancer immunotherapy based on the available data on its promoting function in cancer development and also its expression in cancers of different histological origin. In this review, we will summarize current data on PLAC1 with emphasis on its association with cancer development and immunotherapy. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.